eISSN: 1643-3750


Get your full text copy in PDF

Etoposide added to weekly leucovorin (LV)//5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer

Nicolas Tsavaris, Christos Kosmas, Kostas Gennatas, Maria Vadiaka, Platon Paliaros, Antonis Dimitrakopoulos, Theodoros Diamantis, Heraklis Tsipras, George Papastratis

Med Sci Monit 2002; 8(9): PI65-69

ID: 13494

Background: We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with
relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5- FU.
Material/Methods: Etoposide was administered at 3 different dose levels (DL), in 3 groups of patients (total=60): DL-I – etoposide 80 mg/m2, 45 min i.v. infusion, DL-II – etoposide 120 mg/m2, and DL-III – etoposide 180 mg/m2. In all three levels etoposide was followed by LV 100 mg/m2 i.v., 1-hour infusion, and 5-FU 500 mg/m2 i.v. bolus. Treatment was administered until disease progression
or unacceptable toxicity.
Results: No patients responded at DL-I, while 2 patients at DL-II and 3 at DL-III had a partial response (PR) (P

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree